Gene Expression That Predicts Radiation Exposure in Humans

Total Body Irradiation Clinical Trial

Official title:

Gene Expression That Predicts Radiation Exposure in Humans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03123133
• Other study ID #: DXT-RBT-AB01
• Status: Completed
• Start date: April 6, 2017
• Est. completion date: July 14, 2020

Study information

• Verified date: April 2021
• Source: DxTerity Diagnostics
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To verify and validate a biodosimetry test for determining absorbed ionizing radiation dose by analyzing gene expression signatures of blood samples collected from patients treated with Total Body Irradiation (TBI).

Description:

In order validate the performance of DxTerity's Radiation Biodosimetry Test (RBT) system, several clinical centers will provide controlled, de-identified blood samples and associated clinical information to DxTerity Diagnostics (DxTerity). Variations in dose and frequency of delivery in TBI protocols are expected between the clinical centers and this has been accounted for in the study design. Samples from up to 200 participants will be collected via this protocol. Blood samples for this study will be collected from radiation therapy patients receiving TBI as part of a therapeutic regimen from the site.

Blood samples (up to 4 mL per time point) may be obtained at the time of routine blood collection; participation in this biomarker study will not affect any aspect of patient treatment. Study samples will be obtained prior to, during, and post-radiation treatment regimen. Associated clinical information will be collected from the subject's medical record, as well.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 151
• Est. completion date: July 14, 2020
• Est. primary completion date: April 17, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

1. Male and female patients age 2 or older.

2. Weigh at least 13kg (30lbs), and in the opinion of the investigator, are healthy enough to participate in study activities.

3. Evidence of a personally signed and dated informed consent/assent document indicating that the subject or a legally acceptable representative (parent(s)/legal guardian) has been informed of all pertinent aspects of the study.

4. Diseases treated with HSCT, including malignant and nonmalignant diseases.

5. Planned fractionated total body irradiation (TBI) as part of clinical care with a cumulative dose =6 Gy or a single dose between 1.5 and 3.0 Gy.

Exclusion Criteria:

1. Subjects who have received chemotherapy within 21 days prior to TBI.

2. Concurrent chemotherapy with Fludarabine or an investigational product

3. Cytokine inhibitor or cytokine-inducer therapy within 30 days prior to and during the irradiation regimen

4. Subjects who have received GCSF within 30 days prior to TBI

5. Participants, who in the opinion of the investigator, may not be able to comply with the requirements of the study.

Related Conditions & MeSH terms

• Total Body Irradiation

Locations

Country	Name	City	State
United States	City of Hope	Duarte	California
United States	University of California, Los Angeles, Radiation Oncology	Los Angeles	California
United States	Fred Hutch Cancer Research Center	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
DxTerity Diagnostics	Biomedical Advanced Research and Development Authority

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collection of a sufficient number of blood samples to enable clinical validation of the RBT	Obtain blood samples from 200 TBI patients to analytically validate the Radiation Biodosimetry Test (RBT) System using peripheral blood samples. The RBT should be able to estimate the amount of absorbed radiation that an individual has received from 0 to 10 Gy for up to 7 days post-exposure.	Up to approximately 1 month, from informed consent through completion of blood sample and data collection activities